Quote:

---

Groundbreaking clinical trial achieves 100% remission rate for all cancer patients. This trial is significant because it paves the way for immunotherapy to be used as a first-line treatment for certain types of rectal cancer

---

I was a little shocked when I saw the headline above - thought it meant catastrophe for our CRC trial. But the trial above was exclusively for MSI (microsatellite instability) CRC patients.

Leron's great advantage is that it should work for MSS CRC patients, and that's the group we are study in our combo trial now (assuming the FDA has approved our protocol -- please baby baby baby please). And the MSS group is 85 percent of CRC patients. So we're good.